Wave, RNA Editing
Wave Life Sciences Stock Climbs on RNA Editing Progress
Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T
Wave swells on first RNA editing data in humans
Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its stock even as the news also emerged that Takeda had pulled out of a Huntington's disease alliance with the biotech.
Wave Clinical Trial Shows First Successful RNA Editing in Humans
Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of RNA editing in humans by achieving positive proof-of-mechanism in an early-phase clinical trial.
Wave Life Sciences Shares Surge After RNA Editing Discovery
Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial,
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license rights with $525 million in milestone potential.
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
Shares of Wave Life Sciences surged Wednesday after the company announced "impressive" proof-of-concept results for its new technology.
Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The
Wave Life soars on positive early data for WVE-006
US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD),
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.
RNA-editing stocks soar on Wave Life’s breakthrough trial data
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential treatment for a genetic disorder that causes lung and liver diseases.
FierceBiotech1d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
biopharma-reporter8h
Wave claims first clinical RNA editing title in rare genetic disease
Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...
Wave stock soars 73% on positive data for RNA editing treatment (update)
Wave Life Sciences (NASDAQ:WVE) shares soared 38% in premarket trading Wednesday after the company announced positive ...
Wave sees RNA editing validation in early trial results
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and ...